Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis

Josephine Mauskopf, Sean D. Sullivan, Lieven Annemans et al. · Value in Health · 2007 · 752 citations

Public Affairs, Public Administration, Public Budgeting +12

Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA Study

Tuulikki Sokka, Hannu Kautiainen, Theodore Pincus et al. · Arthritis Research & Therapy · 2010 · 286 citations · Full text

Medicine, Health Sciences, Disability +16

Statistical and regulatory considerations in assessments of interchangeability of biological drug products

László Tóthfalusi, László Endrényi, Shein‐Chung Chow · The European Journal of Health Economics · 2014 · 42 citations · Full text

Pharmacy, Pharmacology, Bioequivalence +16

Budget impact model of rituximab after failure of one or more TNFα inhibitor therapies in the treatment of rheumatoid arthritis

R Launois, Stéphanie Payet, Nathalie Saidenberg-Kermanac’h et al. · Joint Bone Spine · 2008 · 33 citations

Pharmacy, Clinical Sciences, Pharmacotherapy +16

Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries

P.A. Laires, Fernando G. Exposto, Ricardo N. O. Mesquita et al. · The European Journal of Health Economics · 2012 · 31 citations

Medicine, Clinical Sciences, Internal Medicine +15